Virulence: Likely Increased.
Antigenicity: C.37 variant is possibly resistant to therapeutic monoclonal antibodies, natural infection’s or vaccine-induced antibodies.
Spread: Originally was discovered in Peru and has now spread to 29 countries. Variant is dominant in Peru, Chile, Mexico, Equador, but prevalence also growing fast in US, as well as some European countries.
Global Positive Samples Sequenced: 3,256,369
C.37 Sequenced: 5,280
% of Global Samples Sequenced: 0.16%
Distribution of C.37 Sequences Top 5 Countries: Peru 39.0%, Chile 28.0%, United States of America 16.0%, Mexico 4.0%, Ecuador 3.0% – 5,280
Distribution of C.37.1 Sequences Top 5 Countries: United States of America 25.0%, Spain 22.0%, Peru 19.0%, Switzerland 8.0%, Germany 7.0% – 259
Updated September 2021